NCT03592472 is a Phase 3 clinical trial of Pazopanib in Renal Cell Carcinoma, sponsored by Xynomic Pharmaceuticals, Inc..

Who is sponsoring NCT03592472?

NCT03592472 is sponsored by Xynomic Pharmaceuticals, Inc..

What drugs are being tested in NCT03592472?

Interventions in NCT03592472: Pazopanib, Abexinostat, Placebo.

What condition does NCT03592472 study?

NCT03592472 studies Renal Cell Carcinoma.

Is NCT03592472 still recruiting?

NCT03592472 is currently recruiting now. Last updated 13 April 2025.

Last reviewed 2025-04-13 · How we verify

NCT03592472

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Recruiting now Phase 3 Last updated 13 April 2025

What this trial tests

Phase 3 trial testing Pazopanib in Renal Cell Carcinoma in 413 participants. Currently enrolling.

Timeline

17 July 2018

Primary endpoint
30 December 2026

30 June 2028

Quick facts

Lead sponsor	Xynomic Pharmaceuticals, Inc.
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	413
Start date	17 July 2018
Primary completion	30 December 2026
Estimated completion	30 June 2028
Sites	38 locations across Italy, Poland, South Korea, China, United States, Spain

Drugs / interventions tested

Pazopanib — full drug profile →
Abexinostat — full drug profile →
Placebo

Conditions studied

Renal Cell Carcinoma — all drugs for Renal Cell Carcinoma →

Sponsor

Xynomic Pharmaceuticals, Inc.

Who can join

18 and older, any sex, with Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor biomarkers for diagnosis, prognosis and targeted therapy.
Zhou Y, Tao L, Qiu J, Xu J, et al · · 2024 · cited 379× · PMID 38763973 · DOI 10.1038/s41392-024-01823-2
Epigenetics-targeted drugs: current paradigms and future challenges.
Dai W, Qiao X, Fang Y, Guo R, et al · · 2024 · cited 131× · PMID 39592582 · DOI 10.1038/s41392-024-02039-0
Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends.
Nepali K, Liou JP. · · 2021 · cited 122× · PMID 33840388 · DOI 10.1186/s12929-021-00721-x
Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma.
Sharma R, Kadife E, Myers M, Kannourakis G, et al · · 2021 · cited 120× · PMID 34099013 · DOI 10.1186/s13046-021-01961-3
Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases.
Gatla HR, Muniraj N, Thevkar P, Yavvari S, et al · · 2019 · cited 68× · PMID 30841513 · DOI 10.3390/ijms20051110
Targeting epigenetic regulatory machinery to overcome cancer therapy resistance.
Guo L, Lee YT, Zhou Y, Huang Y. · · 2022 · cited 60× · PMID 33421619 · DOI 10.1016/j.semcancer.2020.12.022
The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age.
Huang JJ, Hsieh JJ. · · 2020 · cited 55× · PMID 32130964 · DOI 10.1016/j.semnephrol.2019.12.004
The paradigm of drug resistance in cancer: an epigenetic perspective.
Adhikari S, Bhattacharya A, Adhikary S, Singh V, et al · · 2022 · cited 52× · PMID 35438143 · DOI 10.1042/bsr20211812

Verify or expand the search:

Other trials of Pazopanib

Trials testing the same drug.

NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
NCT07087158 — A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT04199026 — Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sa · NA · recruiting
NCT03850730 — Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia · Phase 1, PHASE2 · unknown
NCT05432791 — Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped W · Phase 2, PHASE3 · active not recruiting

Other recruiting trials for Renal Cell Carcinoma

Currently open trials in the same condition.

NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
NCT07195682 — A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) · Phase 1 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07227402 — A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6 · Phase 3 · recruiting
NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting

Other Xynomic Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT05275374 — XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation · Phase 1, PHASE2 · not yet recruiting
NCT03934567 — A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapse · Phase 2 · active not recruiting
NCT03936153 — Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell L · Phase 2 · recruiting
NCT04024696 — A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients · Phase 1, PHASE2 · active not recruiting
NCT03600441 — Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03592472 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xynomic Pharmaceuticals, Inc.
Last refreshed: 13 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03592472.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing